drugset / Trial / NCT02253823

Multiple Dose Comparison of the Effect of Two Dose Combinations of Tipranavir/Ritonavir (TPV/RTV), on the Pharmacokinetic Characteristics of Efavirenz (Sustiva®) in Healthy Adult Volunteers

NCT02253823

Phase 1 Completed 68 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-label

Summary

The objective of this study was to characterize the effects of two dose combinations of tipranavir/ritonavir (TPV 500 mg/RTV 100 mg and TPV 750 mg/RTV 200 mg), administered daily and BID, on the pharmacokinetics of efavirenz (EFV), 600 mg daily

Timeline

Start
2001-12
Primary completion
2002-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Efavirenz Other / unclassified 600 mg
Subject Ritonavir Other / unclassified 100 mg
Subject Ritonavir Other / unclassified 200 mg
Subject Tipranavir Small molecule 500 mg
Subject Tipranavir Small molecule 750 mg

Indications

No indication recorded.